These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37337892)

  • 1. Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease.
    Demirel M; Köktaşoğlu F; Özkan E; Dulun Ağaç H; Gül AZ; Sharifov R; Sarıkaya U; Başaranoğlu M; Selek Ş
    Scand J Gastroenterol; 2023; 58(11):1344-1350. PubMed ID: 37337892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry.
    Hu C; Wang T; Zhuang X; Sun Q; Wang X; Lin H; Feng M; Zhang J; Cao Q; Jiang Y
    J Transl Med; 2021 Apr; 19(1):152. PubMed ID: 33858428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum untargeted metabolomics delineates the metabolic status in different subtypes of non-alcoholic fatty liver disease.
    Liu L; Zhao J; Zhang R; Wang X; Wang Y; Chen Y; Feng R
    J Pharm Biomed Anal; 2021 Jun; 200():114058. PubMed ID: 33865049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease.
    Ganesan R; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Kim DJ; Suk KT
    Life Sci; 2023 Jun; 322():121626. PubMed ID: 37003543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
    Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
    World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass-Spectrometry-Based Serum Metabolomics of a C57BL/6J Mouse Model of High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Development.
    Lai YS; Chen WC; Kuo TC; Ho CT; Kuo CH; Tseng YJ; Lu KH; Lin SH; Panyod S; Sheen LY
    J Agric Food Chem; 2015 Sep; 63(35):7873-84. PubMed ID: 26262841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D; Marschall HU; Lammert F
    BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study.
    Jin R; Banton S; Tran VT; Konomi JV; Li S; Jones DP; Vos MB
    J Pediatr; 2016 May; 172():14-19.e5. PubMed ID: 26858195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors.
    Tiwari-Heckler S; Gan-Schreier H; Stremmel W; Chamulitrat W; Pathil A
    Nutrients; 2018 May; 10(5):. PubMed ID: 29883377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New aspects characterizing non-obese NAFLD by the analysis of the intestinal flora and metabolites using a mouse model.
    Zhang W; Cheng W; Li J; Huang Z; Lin H; Zhang W
    mSystems; 2024 Mar; 9(3):e0102723. PubMed ID: 38421203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease.
    Barr J; Vázquez-Chantada M; Alonso C; Pérez-Cormenzana M; Mayo R; Galán A; Caballería J; Martín-Duce A; Tran A; Wagner C; Luka Z; Lu SC; Castro A; Le Marchand-Brustel Y; Martínez-Chantar ML; Veyrie N; Clément K; Tordjman J; Gual P; Mato JM
    J Proteome Res; 2010 Sep; 9(9):4501-12. PubMed ID: 20684516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid metabolism in non-alcoholic fatty liver disease in patients with different body weights in mid-mountain conditions].
    Toktogulova NA; Sultanalieva RB; Tuhvatshin RR; Kaliev TK
    Ter Arkh; 2023 Jan; 94(12):1361-1366. PubMed ID: 37167179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct changes in serum metabolites and lipid species in the onset and progression of NAFLD in Obese Chinese.
    Chen J; Lu RS; Diaz-Canestro C; Song E; Jia X; Liu Y; Wang C; Cheung CKY; Panagiotou G; Xu A
    Comput Struct Biotechnol J; 2024 Dec; 23():791-800. PubMed ID: 38318437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome.
    Hamaguchi M; Takeda N; Kojima T; Ohbora A; Kato T; Sarui H; Fukui M; Nagata C; Takeda J
    World J Gastroenterol; 2012 Apr; 18(13):1508-16. PubMed ID: 22509083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population.
    Lee SW; Lee TY; Yang SS; Tung CF; Yeh HZ; Chang CS
    Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):45-48. PubMed ID: 29428103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.